Free Trial

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

$32.13
+0.35 (+1.10%)
(As of 10:32 AM ET)

Collegium Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$40.75
26.83% Upside
High Forecast$44.00
Average Forecast$40.75
Low Forecast$39.00
TypeCurrent Forecast
7/16/23 to 7/15/24
1 Month Ago
6/16/23 to 6/15/24
3 Months Ago
4/17/23 to 4/16/24
1 Year Ago
7/16/22 to 7/16/23
Consensus Rating
Hold
Hold
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$40.75$40.75$39.00$35.00
Forecasted Upside26.83% Upside14.50% Upside9.05% Upside51.82% Upside
Get Collegium Pharmaceutical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

COLL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

COLL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Collegium Pharmaceutical Stock vs. The Competition

TypeCollegium PharmaceuticalMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.71
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside28.23% Upside851.24% Upside9.19% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/7/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$41.00 ➝ $44.00+40.31%
5/10/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Belanger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/10/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Amsellem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$39.00 ➝ $39.00+3.01%
2/26/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$37.00 ➝ $40.00+10.04%
8/4/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:54 AM ET.

COLL Forecast - Frequently Asked Questions

What is Collegium Pharmaceutical's forecast for 2024?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Collegium Pharmaceutical is $40.75, with a high forecast of $44.00 and a low forecast of $39.00.

Should I buy or sell Collegium Pharmaceutical stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" COLL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in COLL, but not buy additional shares or sell existing shares.

Does Collegium Pharmaceutical's stock price have much upside?

According to analysts, Collegium Pharmaceutical's stock has a predicted upside of 14.50% based on their 12-month stock forecasts.

Has Collegium Pharmaceutical been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Collegium Pharmaceutical's stock had 2 downgrades and 1 upgrade by analysts.

What analysts cover Collegium Pharmaceutical?

Collegium Pharmaceutical has been rated by research analysts at Jefferies Financial Group, Needham & Company LLC, and Piper Sandler in the past 90 days.

Do Wall Street analysts like Collegium Pharmaceutical more than its competitors?

Analysts like Collegium Pharmaceutical less than other "medical" companies. The consensus rating for Collegium Pharmaceutical is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how COLL compares to other companies.


This page (NASDAQ:COLL) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners